BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors | Zendy

Santosh Kesari | Zendy; Alberto Bessudo | Zendy; Brian Gastman | Zendy; Anthony P. Conley | Zendy; Victoria Villaflor | Zendy; Lisle M. Nabell | Zendy; DeLisa Madere | Zendy; Emma Chacon | Zendy; Christina Spencer | Zendy; Li Li | Zendy; Christopher Larson | Zendy; Tony Reid | Zendy; Scott Caroen | Zendy; Bryan Oronsky | Zendy; Meaghan Stirn | Zendy; Jeannie Williams | Zendy; Minal Barve | Zendy

Open Access

BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors

Author(s) -

Santosh Kesari,

Alberto Bessudo,

Brian Gastman,

Anthony P. Conley,

Victoria Villaflor,

Lisle M. Nabell,

DeLisa Madere,

Emma Chacon,

Christina Spencer,

Li Li,

Christopher Larson,

Tony Reid,

Scott Caroen,

Bryan Oronsky,

Meaghan Stirn,

Jeannie Williams,

Minal Barve

Publication year - 2022

Publication title -

future oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.857

H-Index - 72

eISSN - 1744-8301

pISSN - 1479-6694

DOI - 10.2217/fon-2022-0481

Subject(s) - medicine , oncolytic virus , immune checkpoint , refractory (planetary science) , cd8 , immunotherapy , clinical trial , cancer research , blockade , cancer immunotherapy , immune system , combination therapy , oncology , immunology , receptor , biology , astrobiology

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research